Edition:
United States

Summit Therapeutics PLC (SUMM.L)

SUMM.L on London Stock Exchange

171.00GBp
--
Change (% chg)

3.50 (+2.09%)
Prev Close
167.50
Open
167.50
Day's High
--
Day's Low
--
Volume
14,120
Avg. Vol
46,282
52-wk High
269.70
52-wk Low
138.14

Latest Key Developments (Source: Significant Developments)

Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress
Wednesday, 4 Oct 2017 07:00am EDT 

Oct 4 (Reuters) - Summit Therapeutics Plc : :Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress.Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS congress.Summit Therapeutics Plc - ‍expect to report first 24-week biopsy, MRI and functional data from phaseout DMD in Q1 2018​.Summit Therapeutics Plc - ‍top-line data from complete 48-week clinical trial expected in Q3 2018​.  Full Article

Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole
Tuesday, 5 Sep 2017 07:00am EDT 

Sept 5 (Reuters) - Summit Therapeutics Plc :Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI.Secondary endpoint of SCR, was achieved in 7 of 14 Ridinilazole treated patients and six of 13 fidaxomicin treated patients.Summit Therapeutics Plc - look forward to initiating phase 3 clinical trials in first half of 2018.  Full Article

Summit Therapeutics reports financial results for Q2 ended July 31 2017
Thursday, 31 Aug 2017 07:00am EDT 

Aug 31 (Reuters) - Summit Therapeutics Plc :Summit Therapeutics reports financial results for the second quarter and half year ended July 31 2017 and operational progress.Summit Therapeutics Plc - ‍revenue was £18.9 million for three months ended 31 July 2017 compared to £nil for three months ended 31 July 2016​.Summit Therapeutics Plc - ‍total comprehensive income for three months ended 31 july 2017 was £10.9 million with a basic earnings per share of 18 pence​.  Full Article

Summit Therapeutics Plc Q1 loss £4.8 million
Wednesday, 14 Jun 2017 07:00am EDT 

June 14 (Reuters) - Summit Therapeutics Plc :Summit Therapeutics reports financial results for the first quarter ended 30 april 2017 and operational progress.Summit Therapeutics Plc - cash and cash equivalents at 30 april 2017 of £19.4 million compared to £28.1 million at 31 january 2017.Summit Therapeutics Plc- loss for three months ended 30 april 2017 of £4.8 million compared to a loss of £5.4 million for three months ended 30 april 2016.  Full Article

Summit Therapeutics says completes enrolment of PhaseOut DMD
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Summit Therapeutics Plc :Summit completes enrolment of PhaseOut DMD, a phase 2 clinical trial of ezutromid in patients with dmd.Summit Therapeutics - with dosing of last patient in trial, co has triggered $22 million milestone payment.$22 million milestone payment is part of company's licence and collaboration agreement with Sarepta Therapeutics Inc.  Full Article

Summit Therapeutics reports loss for year ended 31 January 2017 of 21.4 million pounds
Wednesday, 29 Mar 2017 07:00am EDT 

Summit Therapeutics Plc : Summit Therapeutics reports financial results for the fourth quarter and fiscal year ended 31 January 2017 and operational progress . Summit Therapeutics Plc - loss for year ended 31 January 2017 of 21.4 million pounds compared to a loss of 20.1 million pounds for year ended 31 January 2016 .Summit Therapeutics Plc - believes its existing cash and cash equivalents, including an anticipated $22.0 million payment for a near-term development milestone under licence and collaboration agreement with Sarepta, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements through to 31 December 2018.  Full Article

Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder
Monday, 27 Mar 2017 07:00am EDT 

Summit Therapeutics Plc : Summit Therapeutics Plc - decision follows interim safety review by phaseout dmd's independent data monitoring committee . Summit to extend ongoing phaseout dmd clinical trial of Ezutromid in patients with dmd . Summit Therapeutics Plc - will proceed with planned extension phase of phaseout dmd . Summit Therapeutics Plc - now applied for regulatory approval to extend phaseout dmd from uk medicines, healthcare products regulatory agency, ethics committee . Summit Therapeutics Plc - in addition to extension phase of trial, regulatory submissions also include addition of a safety arm .Summit Therapeutics - safety arm to allow enrolment of patients from phase 1 clinical trials of ezutromid but didn't meet inclusion criteria for phaseout dmd.  Full Article

Summit enrols patients in the U.S. into a mid-stage trial of Ezutromid in patients with DMD
Wednesday, 16 Nov 2016 07:00am EST 

Summit Therapeutics Plc :Summit enrols patients in the United States into PhaseOut DMD, a phase 2 clinical trial of Ezutromid in patients with DMD.  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 07:05am EDT 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 07:00am EDT 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress